Novel combination of insulin degludec and liraglutide (IDegLira) is efficacious across the range of disease progression in type 2 diabetes

被引：0
|
作者：
Rodbard, H. W. [1 ]
Buse, J. B. [2 ]
Woo, V. C. [3 ]
Vilsboll, T. [4 ]
Langbakke, I. [5 ]
Korsholm, L. [5 ]
Gough, S. [6 ]
机构：
[1] Endocrine & Metab Consultants, Rockville, MD USA
[2] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[3] Univ Manitoba, Winnipeg, MB, Canada
[4] Univ Copenhagen, Hellerup, Denmark
[5] Novo Nordisk AS, Soborg, Denmark
[6] Univ Oxford, Oxford OX1 2JD, England
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
835
引用
收藏
页码：S338 / S339
页数：2
相关论文
共 50 条
  • [1] IDegLira, a combination of insulin degludec and liraglutide, is efficacious across the range of disease progression in Type 2 diabetes
    Gough, S. C. L.
    Rodbard, H. W.
    Woo, V. C.
    Langbakke, I. H.
    Korsholm, L.
    Vilsboll, T.
    DIABETIC MEDICINE, 2015, 32 : 75 - 75
  • [2] Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
    Gough, Stephen C. L.
    Jain, Rajeev
    Woo, Vincent C.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (01) : 7 - 19
  • [3] IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, Is Efficacious and Safe in Subjects With Type 2 Diabetes: A Large, Randomized Phase 3 Trial
    Buse, John B.
    Gough, Stephen C. L.
    Woo, Vincent
    Rodbard, Helena W.
    Linjawi, Sultan
    Poulsen, Pernille
    Damgaard, Lars H.
    Bode, Bruce W.
    DIABETES, 2013, 62 : A16 - A16
  • [4] IDegLira Is Efficacious Across the Range of Disease Progression in Type 2 Diabetes (T2D)
    Rodbard, Helena W.
    Buse, John B.
    Woo, Vincent C.
    Vilsboll, Tina
    Langbakke, Irene H.
    Korsholm, Lars
    Gough, Stephen
    DIABETES, 2014, 63 : A18 - A18
  • [5] IDegLira, a novel fixed-ratio combination of insulin degludec and liraglutide, is efficacious and safe in subjects with type 2 diabetes: a large, randomised phase 3 trial
    Gough, S. C. L.
    Buse, J. B.
    Woo, V. C.
    Rodbard, H. W.
    Linjawi, S.
    Poulsen, P.
    Damgaard, L. H.
    Bode, B. W.
    DIABETOLOGIA, 2013, 56 : S96 - S97
  • [6] IDegLira, a novel combination of insulin degludec and liraglutide, is efficacious and safe in subjects with Type 2 diabetes previously treated with oral antidiabetic therapies: a randomised phase 3 trial
    Gough, S. C. L.
    Rodbard, H. W.
    Woo, V. C.
    Linjawi, S.
    Poulsen, P.
    Damgaard, L.
    Bode, B. W.
    DIABETIC MEDICINE, 2014, 31 : 1 - 1
  • [7] Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes
    Vedtofte, Louise
    Knop, Filip K.
    Vilsboll, Tina
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 387 - 396
  • [8] 1.1 IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, is Efficacious and Safe in Subjects with Type 2 Diabetes: A Large, Randomized Phase 3 Trial (65-OR)
    John B. Buse
    Stephen C. Gough
    Vincent C. Woo
    Helena W. Rodbard
    Sultan Linjawi
    Pernille Poulsen
    Lars H. Da mgaard
    Bruce W. Bode
    Nederlands Tijdschrift voor Diabetologie, 2013, 11 (3) : 74 - 75
  • [9] Efficacy and safety of a combination of insulin degludec and liraglutide (IDegLira) in patients with Type 2 diabetes after 1 year of treatment
    Gough, S. C. L.
    Woo, V. C.
    Rodbard, H. W.
    Linjawi, S.
    Poulsen, P.
    Korsholm, L.
    Bode, B. W.
    DIABETIC MEDICINE, 2015, 32 : 76 - 76
  • [10] Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
    Åsa Ericsson
    Adam Lundqvist
    Applied Health Economics and Health Policy, 2017, 15 : 237 - 248
12345